From their website, the n = 180 allows is powered at 90% and I believe they have the opportunity to make adjustments if needed during the course of the trial. They need 125 events showing benefit of 6.5 months vs 3.5 for salvage treatment (a 3 month benefit). On the plus side, the FDA might approve early if it shows efficacy (and safety mimics what was seen in phase 2).
Financing is tricky. From my understanding, their last round of financing gets them through quite a bit of this trial if not all. They raised about 8+ million. And warrants provide them extra if needed. But the market cap is at $20 million so even if they doubled their shares it would still only be 27 million on the market. Waaaaay lower than most biotechs. But doubling never happens. Say its 25% which is still high. That's about 3.5 million more which only puts them at 16 million. Success at phase 3 can EASILY put it at a 300 million dollar valuation which would equal an $18.75 share price at 25% dilution.
So personally, I am confident in the management. They do what they say.
I am comfortable with financing.
I am positive on the trial design and probability of success (especially vs. salvage).
And extremely positive about the opportunities in first line and second line treatment.
And am also extremely positive about efficacy within additional indications.
Seems like a solid bet to me, even though the price is way low. Low volume makes it easy to short.
We shall see.
It took almost a year to kick off the phase III.
Also, the total cohort size is 180? What kind of stat power will that bring?
Will they have enough funding to get to finishline? I see another funding before they finish the phase III. So, I guess it is not a buy just yet.
Recent KTRA News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/25/2024 09:27:10 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/25/2024 09:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2024 09:00:09 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/24/2024 12:35:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/24/2024 12:30:08 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/20/2024 08:20:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 08:15:07 PM
- Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024 • PR Newswire (US) • 09/20/2024 01:25:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/18/2024 12:40:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2024 12:35:07 PM
- Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences • PR Newswire (US) • 09/18/2024 12:30:00 PM
- Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences • PR Newswire (US) • 09/18/2024 12:30:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/11/2024 12:40:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 12:35:09 PM
- Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study • PR Newswire (US) • 09/11/2024 12:30:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/09/2024 08:10:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:05:10 PM
- Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc. • PR Newswire (US) • 09/09/2024 12:30:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/03/2024 09:25:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 09:20:24 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/19/2024 01:10:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 01:05:08 PM
- TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer • PR Newswire (US) • 08/19/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/14/2024 04:15:13 AM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 08/12/2024 09:01:34 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM